BRIEF—David Apelian to quit as COO of Eiger BioPharma

David Apelian will step down as Eiger BioPharmaceuticals’ chief operating officer and executive medical officer, effective June 14, 2019, to become the chief executive at an unnamed private biotech company.

He has held the post at Eiger for the past 17 months.

Dr Apelian will remain actively engaged with Eiger and will continue to serve on Eiger's board of directors, and will consult with the company to assist with the transition.

Eiger plans to announce a new senior executive medical lead in the near future.

David Cory, chief executive at Eiger, commented: "David played an important role in negotiating Phase III D-LIVR study design and endpoints with FDA, allowing Eiger to initiate the first-ever Phase III study in HDV. David has built a strong clinical team, and Eiger is poised to execute across all programs. I wish him well in his new position and look forward to continuing to work with him on our board."